The high prevalence of ARID1A mutations in MSI cancers suggests that it has the potential to be a biomarker predicting sensitivity to immune checkpoint inhibition, along with tumour mutational burden, and TIL and PD-L1 expression, but this will need validation in large clinical trials. Here, ARID1A is linked to neoplasm.